BioMed Valley Discoveries

Focus: BioMed Valley Discoveries is a biotechnology company headquartered in Kansas City, Missouri, focused on small molecule and biologics development. Limited public data available on current scale and market position.

Oncology Hematology

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Open Jobs

About BioMed Valley Discoveries

AI assessmentNot Hiring

No open roles listed right now. Follow BioMed Valley Discoveries to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

19 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Clostridium novyi-NT spores

Solid Tumor Malignancies

Phase 1

Clinical Trials (1)

NCT01924689Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Phase 1

Help build intelligence for BioMed Valley Discoveries

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech with dual modality expertise (small molecules + biologics) offers exposure to diversified drug discovery
Kansas City location provides lower cost of living and potential competitive compensation relative to coasts
Pre-revenue stage allows career builders to shape company culture and processes from the ground up

Watch Out For

Zero active clinical trials and empty pipeline suggest minimal near-term clinical catalysts or revenue visibility
No active job postings indicate the company is not actively hiring or may be in dormant/restructuring phase
Absence of public financials, funding, or press visibility creates uncertainty around runway and strategic direction

Generated by Claude from BioMed Valley Discoveries's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Ulixertinib

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT03454035Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1

Clostridium novyi-NT spores

Solid Tumor Malignancies

Phase 1

Clinical Trials (1)

NCT01118819Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Phase 1

Pembrolizumab

Malignant Neoplasm of Breast

Phase 1

[124I]FIAU

Prosthesis Related Infections

Phase 1

Clinical Trials (1)

NCT01337466Biodistribution and Dosimetry Evaluation of [124I]FIAU

Phase 1

Cetuximab

Metastatic Colorectal Cancer

Phase 1

Clinical Trials (1)

NCT05985954Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1

[14C]-BVD-523

Healthy

Phase 1

Clinical Trials (1)

NCT02994732Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers

Phase 1

Ulixertinib

Gliomas

Phase 1

Clinical Trials (1)

NCT05804227Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas